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Oral cancer is a condition where malignant cells are formed in the 
mouth and throat. These types of cancers are more predominant in 
men than in women, and in the age group of 55-64 years. Oral cancer 
incidence forms 3% of all the malignancies worldwide, and is highest 
in Brazil, France and Asian countries. The variation in incidence and 
pattern of disease can be attributed to the combined effect of ageing of 
the population, as well as to regional differences in the prevalence of 
disease-specific risk factors.1
Oral cancers usually appear as squamous cells forming a thin flat layer 
at the lining of lips, oral cavity and oropharynx region. This is known as 
squamous cell carcinoma (SCC), the commonest cancer type accounting 
for about 96 % of all the cancers in the oral cavity, followed by oral 
squamous cell carcinoma (OSCC), oropharyngeal and pharyngeal SCC, 
which is now ranked 6th amongst other malignancies. The remaining 
oral cancer types include malignant melanomas, salivary gland tumors, 
sarcomas of the soft tissues or jaw bones, non-Hodgkin’s lymphomas and 
metastases from extra-oral primary tumors.
The detection of oral cancer is a crucial process because of its tendency 
to be diagnosed at the later stages, which is detrimental to the patients 
because of its high mortality and morbidity rates (survival rate 15-50%).2 
The mean survival rate of oral cancer patients is up to five years, much 
lower than other cancer types.3 The highest death rate of oral cancers 
is attributed to the low rate of symptoms at the location of metastasis. 
Initially, it exerts no symptoms, being painless until it expands deeper into 
the tissues. Therefore, it is not noticed by the patient in the early stages. 
Prognosis is very bad as it spreads to neck lymph nodes and due to the 
development of undetected secondary lesions. Thus, early detection can 
offer 90% cure and promote long term survival with improved treatment 
outcomes.4
Screening consists of looking for cancer before a person has any 
symptoms. When abnormal tissue or cancer is found early it may be easier 
to treat. Because, by the time symptoms appear, cancer may have already 
begun to spread.  Thus, screening for oral cancer should be standardised 
and applied to the healthy population who are apparently free of disease 
to identify those who may have oral cancer and to distinguish them from 
those who may not. It should be able to identify tissue changes that may 
indicate the likelihood of having or developing the disease in question and 
provide information about the lifestyle pattern and other environmental 
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factors of a patient. Because this would help doctors to 
recommend who should be tested further for cancer, which 
tests should be used, and how often the tests should be 
applied. In addition, such screening program must do no 
harm and be cost effective to the population. The future 
of oral cancer screening must be developed as an on-going 
public health measure for the early detection of the disease.5
Current practice includes screening of the oral cavity 
by a dentist or medical doctor. They examine the site for 
lesions, including areas of leukoplakia (an abnormal white 
patch of cells) and erythroplakia (an abnormal red patch 
of cells) as they may eventually become cancerous.6 But 
this type of screening is associated with major risks, due to 
misdiagnosis, false negative and false positive test results. 
This calls for an urgent need to develop standard or routine 
screening protocols to diagnose cancer.
Several lifestyle factors, particularly tobacco use, affect 
an individual’s risk of developing oral cancer. Worldwide, 
20 to 30% of oral cancer cases are attributable to cigarette 
smoking. Thus, a comprehensive assessment of lifestyle status 
is commonly required, based on demographics (specific 
consideration to age), previous medical history, cancer-
related symptoms, dietary  and oral assessment, current 
medication status, psychosocial behaviour, diet plan and 
swallowing ability, physical activity, social risk factors such as 
smoking history, alcohol or drug use, socioeconomic status, 
availability of a social support system and also assessment 
of the patient and the family s´ cultural and religious belief 
systems.7 The pooled analysis should be developed to 
estimate the effects of lifestyle on cancer development.
Diet or nutrition play an important role in a healthy 
individual for the maintenance of quality of life and among 
cancer patients for their survival. Based on literature, it is 
known that 30% to 87% of cancer patients are diagnosed 
with malnutrition, and 80% of them correspond to oral 
cancer patients, with 30–60% of patients having protein-
calorie malnutrition. Hence, large numbers of patients 
from this group develop clinical symptoms involving the 
gastrointestinal (GI) tract contributing to a compromised 
nutritional status.8 Therefore the goal of screening will be 
to identify patients who present with, or are at a high risk 
for, malnutrition. Earlier studies have validated few tools 
for screening nutritional status using markers of serum 
proteins, anthropometrics data and total body potassium. 
Though these nutritional assessments have shown good 
correlation with serum inflammation markers, a standard 
tool has not been generated for the screening of individual 
cancer. In addition, saliva is another potential body 
fluid bearing enormous information to diagnose cancer.9 
Further assessment of protein, vitamins and minerals in 
serum, saliva and urine samples of an individual will lead 
for an effective screening technique. Thus, the future of 
nutritional screening will identify and prioritize those 
patients at highest nutritional risk that need to be evaluated 
for cancer.
Emotional suppression, distress through feelings of 
helplessness/hopelessness and depression with cancer 
diagnosis can elevate the level of stress markers in an 
individual. If these stress related markers in serum and 
saliva are assessed, the cancer status can be established. It is 
clear that cancer patients experience physical, emotional and 
social losses during treatment and this has to be differentiated 
from issues of healthy individuals. Various oxidative 
stress markers in saliva and serum have been evaluated in 
different populations around the world. But the techniques 
are not validated specifically for cancer diagnosis. Stress 
assessment in conjugation with psychosocial behaviour 
needs to be studied. Individuals who live alone or who 
are under social deprivation and isolation are at increased 
risk of stress. Therefore, it is important to understand the 
variety and causes of the stress. A boundary line should be 
developed to separate the cancer-generated from the normal 
self-generated stress. 
The development of tumorigenic disease is associated 
with genotypic and phenotypic alterations such as activation 
of protoncogenes and oncogenes along with the inactivation 
of tumor suppressor genes. These variations in genetic 
factors are expressed by the affected cells or cancerous 
tissue. Typical changes in the DNA of dysplastic or 
cancer cells commonly include point mutations, deletions, 
translocations, amplifications and methylations, as well as 
changes in cyclin D1, epidermal growth factor receptor 
(EGFR), microsatellite instability and HPV presence.10
 It has been studied that nucleic acids and proteins related 
to cancer cells can be detected in plasma/serum, urine, 
saliva and other bodily fluids. Hence, these nucleic acids 
and proteins can be used as molecular markers for the early 
diagnosis of the disease and as recurrence markers to deal 
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with the treatment of cancer. 
The methods presently available in the literature are not 
ready for immediate clinical use as diagnostic tools. Hence, 
research to develop a simple, efficient, fast, portable and 
cost-effective screening tool for oral cancer is the need of 
the hour.
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